3DBio Therapeutics
Kevin Slawin, MD., is the Founder and Managing Partner of Rapha Capital Management, LLC. He is a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) and the Vanguard Urologic Institute at Memorial Hermann Medical Group in Houston, Texas, where he was also the Director of Urology at Memorial Hermann Hospital. Slawin graduated, magna cum laude, with a Bachelor of Arts degree in Biochemistry from Columbia University, and earned his medical degree in 1986 from Columbia College of Physicians and Surgeons, and was elected to the Alpha Omega Alpha honor society.
This person is not in any offices
3DBio Therapeutics
3DBio Therapeutics is a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow the replacement of each individual patient’s parts with tissues designed and created specifically for them. 3DBio has developed unique capabilities toward the creation of living tissue implants for therapeutic applications.